Genentech, Inc.
1 DNA Way
South San Francisco
California
94080-4990
United States
Tel: 650-225-1000
Fax: 650-225-6000
Website: http://www.gene.com/
About Genentech, Inc.
Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for over 40 years. Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. We are among the world's leading biotech companies, with multiple products on the market and a promising development pipeline. Please take this opportunity to learn about Genentech where we believe that our employees are our most important asset & are dedicated to remaining a great place to work.
Connect with us!
Being a scientist at Genentech means being a drug discoverer. Mike Varney, head of Genentech Research and Early Development, explains how this culture of innovation is helping to solve some of the hardest biomedical problems of our time.
1139 articles with Genentech, Inc.
-
Rob Dunn, a professor of applied ecology at North Carolina State University in Raleigh recently wrote a book, Never Home Alone. In this book, he describes how millions of microorganisms, bacteria, fungi, viruses, parasites and insects live in your home—and in and on your body.
-
FDA Grants Priority Review to Genentech’s Tecentriq in Combination with Abraxane for the Initial Treatment of People with PD-L1-Positive, Metastatic Triple-Negative Breast Cancer
11/13/2018
Triple-negative breast cancer is an aggressive disease, with high unmet medical need
-
BioSpace Movers and Shakers Nov. 12
11/12/2018
Biopharma companies name new members of their leadership teams. Who made big moves this week? -
Biodesix Test Predicts Response to Atezolizumab in Lung Cancer
11/12/2018
Researchers with Biodesix® and Genentech, a member of the Roche Group, today presented findings on a test designed to predict response to atezolizumab (Tecentriq®) in patients with non-small cell lung cancer (NSCLC).
-
Over 76 Data Driven Presentations on Cancer Treatment Research to be Presented at the 9th Annual World Antibody-Drug Conjugate Conference in San Diego, November 12-15
11/8/2018
The Antibody-Drug Conjugate community will join together for the 9th World ADC San Diego on November 12-15 at the Marriott Marquis San Diego with key influential researchers from around the world, to discuss clinical research experiences to help further the development of cancer therapeutics.
-
This year has been a strong one for biotech initial public offerings (IPO). According to the Wall Street Journal, as of mid-October, 55 biotech companies had raised $5.75 billion.
-
In October 1982, the Food and Drug Administration (FDA) approved Eli Lilly and Company’s Humulin, the first human insulin for diabetes treatment created using recombinant DNA technology.
-
A study evaluated fixed-duration the two companies’ Venclexta/Venclyxto (venetoclax) in combination with Genentech’s Gazyva/Gazyvaro (obinutuzumab) in patients with previously untreated chronic lymphocytic leukemia (CLL) and co-existing medical conditions.
-
Genentech to Present New Data from Its Industry-Leading Hematology Portfolio at the American Society of Hematology (ASH) 2018 Annual Meeting
11/1/2018
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data for its approved and investigational medicines across a range of blood diseases, and including several first-in-class medicines, will be presented at the 60th American Society of Hematology (ASH) Annual Meeting
-
Phase III Data Showed That Venclexta Plus Gazyva Reduced the Risk of Disease Worsening or Death in People With Previously Untreated Chronic Lymphocytic Leukemia With Co-Morbidities
10/31/2018
The Phase III CLL14 study compared Venclexta in combination with Gazyva to standard-of-care Gazyva plus chlorambucil
-
Four former Genentech employees have been indicted by a federal grand jury for the alleged theft of company trade secrets in order to help a company set up in Taiwan develop drugs similar to those made by the Roche subsidiary.
-
Roche announced positive data from its Phase II STAIRWAY clinical trial. The trial evaluated the extended durability of faricimab (RG7716) in the treatment of neovascular (wet) age-related macular degeneration (nAMD).
-
New Stairway Study Data Shows Potential for Extended Durability with Faricimab in Wet Age-Related Macular Degeneration (AMD)
10/27/2018
Faricimab – the first bispecific antibody designed for the eye – dosed every four months demonstrated sustained vision outcomes compared to monthly ranibizumab for people with wet AMD1
-
Xofluza (baloxavir marboxil) was approved for the treatment of acute, uncomplicated influenza, or flu, in people 12 years of age and older. The new medication has a novel mechanism of action that, Roche said, inhibits polymerase acidic endonuclease, an enzyme that is essential for the flu virus t...
-
Syros Pharma and Genentech: Corporate Culture Enhanced and Defined by Non-Work Activities
10/25/2018
What is presumably good humor, Cambridge, Mass.-based Syros Pharmaceuticals held its third annual Lab Olympics, where various executives in the company competed in a range of contests that included a race to put on safety equipment and accuracy in pipetting. -
Genentech Announces FDA Approval of XOFLUZA (Baloxavir Marboxil) for Influenza
10/24/2018
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Food and Drug Administration (FDA) has approved XOFLUZA™ (baloxavir marboxil) for the treatment of acute, uncomplicated influenza, or flu, in people 12 years of age and older.
-
Mesothelioma is a rare cancer that develops in the lining of the lungs, abdomen, or cardiovascular cavity. A 2017 study reported that the number of people affected by this rare cancer is between 2,400 - 2,800 individuals per year in the United States alone.
-
Genentech’s Tecentriq Plus Chemotherapy (Carboplatin and Abraxane) as an Initial Treatment Helped People With Advanced Non-Squamous Non-Small Cell Lung Cancer Live Significantly Longer Compared to Chemotherapy Alone
10/22/2018
The Phase III IMpower130 study investigating the Tecentriq plus chemotherapy combination demonstrated a significant overall survival (OS) and progression-free survival (PFS) benefit
-
Updated with Exclusive | ESMO 2018: 60% of Ovarian Cancer Patients Receiving Lynparza Were Progre...
10/22/2018
AstraZeneca and Merck & Co. presented results at the Presidential Symposium at the European Society for Medical Oncology 2018 Congress held in Munich Germany describing its Phase III SOLO-1 trial of Lynparza (olaparib) in ovarian cancer. -
The European Society of Medical Oncology was in full swing this weekend as multiple companies showed off mid- and late-stage assets that could change the way some patients are treated for their cancer. This morning, BioSpace takes a look at some of the announcements.